Anti-Human IgE/IGHE Reference Antibody (Ligelizumab, RUO) (HV064026)

Name: Anti-Human IgE/IGHE Reference Antibody (Ligelizumab, RUO)
Brand: abinScience
SKU: HV064026
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HV064026
Description	Ligelizumab (HV064026) is a research-grade recombinant antibody targeting Ig epsilon chain C region. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa
Cible	IGHE, Ig epsilon chain C region, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P01854
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	CL-2C, 1322627-61-1
Contexte	Immunoglobulin heavy constant epsilon (IgE/IGHE) is a ~59 kDa protein. Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. 1. Schroeder, HW. et al. (2010) The Journal of allergy and clinical immunology 125, S41-52. PMID: 20176268 2. McHeyzer-Williams, M. et al. (2011) Nature reviews. Immunology 12, 24-34. PMID: 22158414 3. Teng, G. et al. (2007) Annual review of genetics 41, 107-20. PMID: 17576170
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)